Embla Medical hf (OCSE:EMBLA) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:EMBLA Embla Medical hf OCSE:EMBLA
92 GF Score
Price kr28.95
GF Value kr34.11
Valuation Modestly Undervalued
View Full Analysis

What is Embla Medical hf FFO?

FFO (Funds from operations) only applies to REITs.

OCSE:EMBLA
92GF Score
Embla Medical hf OCSE:EMBLA
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Embla Medical hf (OCSE:EMBLA) Overvalued in 2026?

Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued. The current stock price of kr28.95 is trading 15.1% below its estimated GF Value™ of kr34.11. GuruFocus considers Embla Medical hf to be Modestly Undervalued.

Key valuation signals for OCSE:EMBLA:

  • FFO:
  • GF Value™: kr34.11 vs. price of kr28.95 (15.1% below fair value)
  • GF Score™: 92/100

No single metric tells the full story. See the OCSE:EMBLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Embla Medical hf Business Description

Other Exchanges 0FIW:UK5IQ:Germany
Address Grjothals 5, Reykjavik, ISL
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
92GF Score

Get the complete analysis for OCSE:EMBLA

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr28.95
Price
kr34.11
GF Value